according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

SECTION 1. IDENTIFICATION

Product name : Dexamethasone / Chlorphenamine Hydrogen Maleate Formu-

lation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary medicine Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Eye irritation : Category 2A

Respiratory sensitization : Category 1

Skin sensitization : Category 1

Specific target organ toxicity

- repeated exposure (Oral)

Category 1 (ear, Kidney, inner ear)

Specific target organ toxicity

- repeated exposure (Oral)

Category 2 (Cardio-vascular system)

Other hazards

None known.

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.

H319 Causes serious eye irritation.

H334 May cause allergy or asthma symptoms or breathing diffi-

culties if inhaled.

H372 Causes damage to organs (ear, Kidney, inner ear) through prolonged or repeated exposure if swallowed.

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

H373 May cause damage to organs (Cardio-vascular system)

through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of

the workplace.

P280 Wear protective gloves, eye protection and face protec-

tion.

P285 In case of inadequate ventilation wear respiratory protec-

tion.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

P333 + P313 If skin irritation or rash occurs: Get medical atten-

tion.

P337 + P313 If eye irritation persists: Get medical attention.

P342 + P311 If experiencing respiratory symptoms: Call a doc-

tor.

P362 + P364 Take off contaminated clothing and wash it before

reuse.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Dihydrostreptomycin sul- phate	5490-27-7*	>= 45 - <= 70	TSC
2-(4- Aminobenzo- yloxy)ethyldiethylammonium (6R)-6-(2- phenylacetam- ido)penicillanate monohy- drate	6130-64-9*	>= 15 - <= 40	TSC
Procaine hydrochloride	51-05-8*	>= 1 - <= 5	TSC

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

Chlorphenamine hydrogen maleate	113-92-8*	>= 0.5 - <= 1.5	TSC
dexamethasone	50-02-2*	<= 0.1	TSC

^{*} Indicates that the identifier is a CAS No.

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis,

reactive airways dysfunction syndrome).

May cause an allergic skin reaction.

Causes serious eye irritation.

May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

TSC- the actual concentration or concentration range is withheld as a trade secret

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides

Chlorine compounds

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid rele

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Dihydrostreptomycin sulphate	5490-27-7	TWA	4 mg/m3 (OEB 1)		
	Further information: OTO				
Chlorphenamine hydrogen maleate	113-92-8	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	100 μg/100 cm2	Internal	
dexamethasone	50-02-2	TWA	10 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	100 µg/100 cm ²	Internal	

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

disposable suits) to avoid exposed skill sulfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Color : white

Odor : No data available

Odor Threshold : No data available

pH : 5.0 - 6.0

No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1.17 - 1.21 g/cm³

No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

Dihydrostreptomycin sulphate:

Acute oral toxicity : LD50 (Rat): 9,000 - 25,000 mg/kg

LD50 Oral (Mouse): 30,000 mg/kg

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Acute oral toxicity : LD50 (Mouse): > 2,000 mg/kg

Procaine hydrochloride:

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen **Maleate Formulation**

Version SDS Number: Date of last issue: 02/25/2025 Revision Date: 04/14/2025 5491621-00014 Date of first issue: 03/10/2020 4.0

: LD50 (Rat): 200 mg/kg Acute oral toxicity

Chlorphenamine hydrogen maleate:

Acute inhalation toxicity LC50 (Rat): 0.61 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of : LD50 (Rat): 89 mg/kg

administration)

dexamethasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 6,500 mg/kg

Acute toxicity (other routes of : LD50 (Rat): 14 mg/kg

administration)

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate

monohydrate:

Result No skin irritation

Chlorphenamine hydrogen maleate:

Species Rabbit

Result No skin irritation

dexamethasone:

Species Rabbit

Result Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate

monohydrate:

Result No eye irritation

Chlorphenamine hydrogen maleate:

Species Rabbit

Result Severe irritation

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

dexamethasone:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : positive

Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitization in humans

Assessment : Probability of respiratory sensitization in humans based on

animal testing

Chlorphenamine hydrogen maleate:

Routes of exposure : Dermal

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Test system: Human lymphocytes

Result: negative

Procaine hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

Chlorphenamine hydrogen maleate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen **Maleate Formulation**

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 04/14/2025 5491621-00014 Date of first issue: 03/10/2020 4.0

Test Type: Mouse Lymphoma

Result: negative

Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells

Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Germ cell mutagenicity -

Assessment

: Weight of evidence does not support classification as a germ

cell mutagen.

dexamethasone:

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo Test Type: Micronucleus test

> Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 5 mg/kg
Result : negative **Species**

: 5 mg/kg body weight

Result

Chlorphenamine hydrogen maleate:

Species: RatApplication Route: OralExposure time: 2 YearsNOAEL: 30 - 60 r Species

: 30 - 60 mg/kg body weight

Result : negative

Mouse Species Application Route Oral Exposure time 2 Years

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

NOAEL : 20 - 50 mg/kg body weight

Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Dihydrostreptomycin sulphate:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 5 mg/kg body weight

Test Type: Embryo-fetal development

Species: Guinea pig

Application Route: Intramuscular

General Toxicity Maternal: LOAEL: 100 - 200 mg/kg body

weight

Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: Maternal toxicity observed., Embryotoxic effects and

adverse effects on the offspring were detected.

Chlorphenamine hydrogen maleate:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: LOAEL: 20 mg/kg body weight

Result: No effects on fertility., No effects on fetal development.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Reduced embryonic survival, No malformations were

observed.

Remarks: The significance of these findings for humans is not

certain.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

Developmental Toxicity: LOAEL: 15 mg/kg body weight Result: No significant adverse effects were reported

dexamethasone:

Effects on fetal development : Test Type: Development

Species: Mouse

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 6 mg/kg body weight Result: Specific developmental abnormalities., Cleft palate

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: NOAEL: 0.025 mg/kg body weight

Result: Specific developmental abnormalities.

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: >= 0.062 mg/kg body weight

Result: Specific developmental abnormalities.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: >= 0.02 mg/kg body weight

Result: Skeletal and visceral variations., Fetal growth

retardation

Reproductive toxicity - As-

sessment

: May damage the unborn child.

STOT-single exposure

Not classified based on available information.

Components:

Chlorphenamine hydrogen maleate:

Assessment : May cause drowsiness or dizziness.

STOT-repeated exposure

Causes damage to organs (ear, Kidney, inner ear) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Components:

Dihydrostreptomycin sulphate:

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Chlorphenamine hydrogen maleate:

Target Organs : Cardio-vascular system

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen **Maleate Formulation**

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 04/14/2025 5491621-00014 Date of first issue: 03/10/2020 4.0

May cause damage to organs through prolonged or repeated Assessment

exposure.

dexamethasone:

Routes of exposure : Oral

Target Organs : Adrenal gland, Immune system, thymus gland

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Dihydrostreptomycin sulphate:

Dihydrosuepto...,
Species
LOAEL
Application Route
Exposure time
Target Organs Guinea pig : 40 mg/kg : Oral : 90 d : ear

Symptoms hearing loss

Application Route
Exposure time
Target Organ Species Cat 100 mg/kg Oral 60 d ear

Symptoms ataxia, hearing loss, Reduced body weight

Species Cat LOAEL 300 mg/kg Application Route Oral Exposure time : 21 d Target Organs ear

Symptoms ataxia, hearing loss, Reduced body weight

Chlorphenamine hydrogen maleate:

Species NOAEL 10 mg/kg באוקקיוסת Route Exposure time Remarks : Oral 6 Weeks

Remarks : No significant adverse effects were reported

Species LOAEL Application Route : Monkey : 15 mg/kg : Oral Exposure time : 105 Weeks Target Organs Heart

dexamethasone:

Species Rat

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen **Maleate Formulation**

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 04/14/2025 5491621-00014 Date of first issue: 03/10/2020 4.0

NOAEL 0.0015 mg/kg

Application Route
Exposure time
Target Organs
Remarks Oral : 7 d : Liver

Remarks : Significant toxicity observed in testing

Species Rat

LOAEL 0.003 mg/kg

Application Route Exposure time Oral 90 d

Target Organs Blood, Adrenal gland, thymus gland Remarks Significant toxicity observed in testing

Species LOAEL Application Route Exposure time Target Organs Remarks 0.125 mg/kg Oral : 6 Weeks : Adrenal gland

Remarks Significant toxicity observed in testing

Species Rat LOAEL : 0.4 mg/kg LOAEL
Application Route
Exposure time
Target Organs
Remarks : Oral : 3 Months : Immune system

: Significant toxicity observed in testing Remarks

Species Dog LOAEL 8 mg/kg Application Route Exposure time Oral 3 Months Target Organs Immune system

Remarks Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Dihydrostreptomycin sulphate:

General Information Symptoms: Erythema, hearing loss, Nausea, Rash, Vomiting,

Headache, hypotension

Chlorphenamine hydrogen maleate:

Inhalation : Symptoms: central nervous system effects

Remarks: May cause respiratory tract irritation.

Remarks: May irritate skin. Skin contact : Symptoms: Eye irritation Eye contact

Remarks: May cause irreversible eye damage.

Symptoms: central nervous system effects Ingestion

Remarks: Based on Human Evidence

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

dexamethasone:

Ingestion : Target Organs: Immune system

Target Organs: Adrenal gland

Target Organs: Bone

Symptoms: muscle weakness

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-phenylacetamido)penicillanate monohydrate:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Procaine hydrochloride:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

dexamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 56 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.033 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

dexamethasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 3.54 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Procaine hydrochloride:

Partition coefficient: n-

octanol/water

: log Pow: 1.389

dexamethasone:

Partition coefficient: n-

octanol/water

log Pow: 1.83

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Respiratory or skin sensitization

Specific target organ toxicity (single or repeated exposure)

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Dihydrostreptomycin sulphate 5490-27-7 2-(4-Aminobenzoyloxy)ethyldiethylammonium (6R)-6-(2-6130-64-9

phenylacetamido)penicillanate monohydrate

Water 7732-18-5

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information


according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen Maleate Formulation

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 4.0 04/14/2025 5491621-00014 Date of first issue: 03/10/2020

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act: CMR - Carcinogen, Mutagen or Reproductive Toxicant: DIN - Standard of the German Institute for Standardisation: DOT - Department of Transportation: DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship: RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act

according to the OSHA Hazard Communication Standard



Dexamethasone / Chlorphenamine Hydrogen **Maleate Formulation**

Version Revision Date: SDS Number: Date of last issue: 02/25/2025 04/14/2025 5491621-00014 Date of first issue: 03/10/2020 4.0

(United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date 04/14/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8